Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Suppr

超能文献

作者信息

Preac-Mursic V, Wilske B, Schierz G, Süss E, Gross B

机构信息

Max von Pettenkofer Institute for Hygiene and Medical Microbiology, University of Munich, FRG.

出版信息

Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):651-3. doi: 10.1007/BF01968150.

DOI:10.1007/BF01968150

PMID:2550233

Abstract

The in vitro and in vivo activity of the new macrolides azithromycin, clarithromycin and roxythromycin was compared with that of erythromycin against Borrelia burgdorferi. In in vitro tests using ten clinical isolates all macrolides were highly active against Borrelia burgdorferi (MIC90 0.015-0.06 micrograms/ml). Azithromycin was more potent than the other macrolides in experimental animal infection, eradicating the organism in all animals tested at a dosage of 8 mg/kg.

摘要

相似文献

Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.

Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):651-3. doi: 10.1007/BF01968150.

Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.

Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):838-41. doi: 10.1007/BF01967388.

Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin.

Eur J Clin Microbiol Infect Dis. 1993 Feb;12(2):131-3. doi: 10.1007/BF01967591.

Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.

Antimicrob Agents Chemother. 1989 Apr;33(4):591-2. doi: 10.1128/AAC.33.4.591.

In-vitro activity of ciprofloxacin, temafloxacin, azithromycin, clarithromycin and metronidazole against Giardia lamblia.

J Antimicrob Chemother. 1993 Apr;31(4):615-7. doi: 10.1093/jac/31.4.615.

Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.

Eur J Clin Microbiol Infect Dis. 1989 Jul;8(7):653-4. doi: 10.1007/BF01968151.

In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Antimicrob Agents Chemother. 1988 Oct;32(10):1500-2. doi: 10.1128/AAC.32.10.1500.

Comparative in vitro activity of A-56268.

Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):798-802. doi: 10.1007/BF01975054.

Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Antimicrob Agents Chemother. 2004 Jan;48(1):344-7. doi: 10.1128/AAC.48.1.344-347.2004.

In-vitro activity of quinolones and macrolides against mycobacteria.

J Antimicrob Chemother. 1994 Sep;34(3):343-51. doi: 10.1093/jac/34.3.343.

引用本文的文献

Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Expert Rev Anti Infect Ther. 2014 Sep;12(9):1103-35. doi: 10.1586/14787210.2014.940900. Epub 2014 Jul 30.

Antibiotic treatment of animals infected with Borrelia burgdorferi.

Clin Microbiol Rev. 2009 Jul;22(3):387-95. doi: 10.1128/CMR.00004-09.

Evidence of a conjugal erythromycin resistance element in the Lyme disease spirochete Borrelia burgdorferi.

Int J Antimicrob Agents. 2007 Dec;30(6):496-504. doi: 10.1016/j.ijantimicag.2007.07.013. Epub 2007 Oct 1.

Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi.

Antimicrob Agents Chemother. 2004 Jan;48(1):344-7. doi: 10.1128/AAC.48.1.344-347.2004.

In vitro activity of trimethoprim against Borrelia burgdorferi.

Eur J Clin Microbiol Infect Dis. 1997 Jun;16(6):458-60. doi: 10.1007/BF02471911.

Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

J Clin Microbiol. 1997 Jan;35(1):111-6. doi: 10.1128/jcm.35.1.111-116.1997.

Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans.

Infection. 1996 Jan-Feb;24(1):64-8. doi: 10.1007/BF01780661.

Clarithromycin in treatment of early Lyme disease: a pilot study.

Antimicrob Agents Chemother. 1996 Feb;40(2):468-9. doi: 10.1128/AAC.40.2.468.

Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.

Infection. 1993 Mar-Apr;21(2):83-8. doi: 10.1007/BF01710737.

In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents.

Antimicrob Agents Chemother. 1993 Jul;37(7):1444-6. doi: 10.1128/AAC.37.7.1444.

本文引用的文献

Treatment of Lyme disease.

Ann Intern Med. 1981 Jan;94(1):137. doi: 10.7326/0003-4819-94-1-137_2.

Serological diagnosis of erythema migrans disease and related disorders.

Infection. 1984 Sep-Oct;12(5):331-7. doi: 10.1007/BF01651147.

Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin.

Ann Intern Med. 1983 Dec;99(6):767-72. doi: 10.7326/0003-4819-99-6-767.

In vitro and in vivo susceptibility of Borrelia burgdorferi.

Eur J Clin Microbiol. 1987 Aug;6(4):424-6. doi: 10.1007/BF02013102.

European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility.

Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Dec;263(1-2):112-8. doi: 10.1016/s0176-6724(86)80110-9.

In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.

Antimicrob Agents Chemother. 1987 Feb;31(2):164-7. doi: 10.1128/AAC.31.2.164.

Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides.

Antimicrob Agents Chemother. 1988 Nov;32(11):1710-9. doi: 10.1128/AAC.32.11.1710.

Comparative in vitro activity, serum binding and binding activity interactions of the macrolides A-56268, RU-28965, erythromycin and josamycin.

Drugs Exp Clin Res. 1987;13(9):567-76.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验